Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

Umang Swami; Brian Swick; Yousef Zakharia; Mohammed Milhem

doi:10.1155/2019/4683531

Back

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

Journal article

Open access

Peer reviewed

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

Umang Swami, Brian Swick, Yousef Zakharia and Mohammed Milhem

Case reports in oncological medicine, Vol.2019, 4683531

01/01/2019

DOI: 10.1155/2019/4683531

PMCID: PMC6431461

PMID: 30963012

Files and links (1)

url

https://doi.org/10.1155/2019/4683531View

Published (Version of record) Open Access

Abstract

Talimogene laherparepvec is a novel, genetically engineered, oncolytic herpes virus approved for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. It is administered as an intralesional injection. However, if the lesion continues to persist, it presents with a clinical challenge as when to stop treatment. Herein, we present two cases from our institution wherein the disease appeared to be persistent radiologically; however, on pathological excision, there was no evidence of disease and patients continue to be in durable remission after stopping treatment.

Oncology

Life Sciences & Biomedicine

Science & Technology

Details

Title: Subtitle: Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
Creators: Umang Swami - University of Iowa
Brian Swick - University of Iowa Hospitals and Clinics
Yousef Zakharia - University of Iowa Hospitals and Clinics
Mohammed Milhem - University of Iowa Hospitals and Clinics
Resource Type: Journal article
Publication Details: Case reports in oncological medicine, Vol.2019, 4683531
DOI: 10.1155/2019/4683531
PMID: 30963012
PMCID: PMC6431461
NLM abbreviation: Case Rep Oncol Med
ISSN: 2090-6706
eISSN: 2090-6714
Publisher: Hindawi Publishing Group
Number of pages: 5
Grant note: P30 CA086862 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA086862 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Language: English
Date published: 01/01/2019
Academic Unit: Dermatology; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Internal Medicine
Record Identifier: 9984548381102771

Metrics

7 Record Views

1 Times Cited - Web of Science